144 related articles for article (PubMed ID: 8505335)
21. Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin.
Podor TJ; Peterson CB; Lawrence DA; Stefansson S; Shaughnessy SG; Foulon DM; Butcher M; Weitz JI
J Biol Chem; 2000 Jun; 275(26):19788-94. PubMed ID: 10764803
[TBL] [Abstract][Full Text] [Related]
22. Binding of tissue-type plasminogen activator with human endothelial cell monolayers. Characterization of the high affinity interaction with plasminogen activator inhibitor-1.
Russell ME; Quertermous T; Declerck PJ; Collen D; Haber E; Homcy CJ
J Biol Chem; 1990 Feb; 265(5):2569-75. PubMed ID: 2105930
[TBL] [Abstract][Full Text] [Related]
23. Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator.
Keijer J; Ehrlich HJ; Linders M; Preissner KT; Pannekoek H
J Biol Chem; 1991 Jun; 266(16):10700-7. PubMed ID: 1709939
[TBL] [Abstract][Full Text] [Related]
24. Interactions between tissue-type plasminogen activator and extracellular matrix-associated plasminogen activator inhibitor type 1 in the human hepatoma cell line HepG2.
Owensby DA; Morton PA; Schwartz AL
J Biol Chem; 1989 Oct; 264(30):18180-7. PubMed ID: 2553701
[TBL] [Abstract][Full Text] [Related]
25. Receptor-mediated endocytosis of tissue-type plasminogen activator by low density lipoprotein receptor-related protein on human hepatoma HepG2 cells.
Bu G; Maksymovitch EA; Schwartz AL
J Biol Chem; 1993 Jun; 268(17):13002-9. PubMed ID: 8389767
[TBL] [Abstract][Full Text] [Related]
26. The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator.
Lindahl TL; Ohlsson PI; Wiman B
Biochem J; 1990 Jan; 265(1):109-13. PubMed ID: 2105714
[TBL] [Abstract][Full Text] [Related]
27. Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop.
Audenaert AM; Knockaert I; Collen D; Declerck PJ
J Biol Chem; 1994 Jul; 269(30):19559-64. PubMed ID: 8034724
[TBL] [Abstract][Full Text] [Related]
28. The role of plasminogen activator inhibitor type 1 in the clearance of tissue-type plasminogen activator by rat hepatoma cells.
Camani C; Bachmann F; Kruithof EK
J Biol Chem; 1994 Feb; 269(8):5770-5. PubMed ID: 8119917
[TBL] [Abstract][Full Text] [Related]
29. A plasminogen activator inhibitor-2 from a promyelocytic leukemia cell line, PL-21, binds to the carboxy-terminal chain of plasminogen activators.
Takeuchi T; Niiya K; Kubonishi I; Miyoshi I
Thromb Haemost; 1990 Apr; 63(2):259-64. PubMed ID: 2363126
[TBL] [Abstract][Full Text] [Related]
30. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin).
Declerck PJ; De Mol M; Alessi MC; Baudner S; Pâques EP; Preissner KT; Müller-Berghaus G; Collen D
J Biol Chem; 1988 Oct; 263(30):15454-61. PubMed ID: 2459123
[TBL] [Abstract][Full Text] [Related]
31. The composition of complexes between plasminogen activator inhibitor 1, vitronectin and either thrombin or tissue-type plasminogen activator.
van Meijer M; Stoop A; Smilde A; Preissner KT; van Zonneveld AJ; Pannekoek H
Thromb Haemost; 1997 Mar; 77(3):516-21. PubMed ID: 9066004
[TBL] [Abstract][Full Text] [Related]
32. Mutants of plasminogen activator inhibitor-1 designed to inhibit neutrophil elastase and cathepsin G are more effective in vivo than their endogenous inhibitors.
Stefansson S; Yepes M; Gorlatova N; Day DE; Moore EG; Zabaleta A; McMahon GA; Lawrence DA
J Biol Chem; 2004 Jul; 279(29):29981-7. PubMed ID: 15131125
[TBL] [Abstract][Full Text] [Related]
33. Resolution of Michaelis complex, acylation, and conformational change steps in the reactions of the serpin, plasminogen activator inhibitor-1, with tissue plasminogen activator and trypsin.
Olson ST; Swanson R; Day D; Verhamme I; Kvassman J; Shore JD
Biochemistry; 2001 Oct; 40(39):11742-56. PubMed ID: 11570875
[TBL] [Abstract][Full Text] [Related]
34. Conformational changes of the reactive-centre loop and beta-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1.
Kjøller L; Martensen PM; Sottrup-Jensen L; Justesen J; Rodenburg KW; Andreasen PA
Eur J Biochem; 1996 Oct; 241(1):38-46. PubMed ID: 8898886
[TBL] [Abstract][Full Text] [Related]
35. Effect of type-1 plasminogen activator inhibitor on human leukocyte elastase.
Abe H; Matsuda E; Binder BR
Thromb Res; 1994 Mar; 73(6):361-9. PubMed ID: 7521069
[TBL] [Abstract][Full Text] [Related]
36. Plasminogen activator inhibitor-1 is the primary inhibitor of tissue-type plasminogen activator in pregnancy plasma.
Jørgensen M; Philips M; Thorsen S; Selmer J; Zeuthen J
Thromb Haemost; 1987 Oct; 58(3):872-8. PubMed ID: 3124286
[TBL] [Abstract][Full Text] [Related]
37. A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate.
Urano T; Strandberg L; Johansson LB; Ny T
Eur J Biochem; 1992 Nov; 209(3):985-92. PubMed ID: 1425706
[TBL] [Abstract][Full Text] [Related]
38. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
39. Cellular degradation of free and inhibitor-bound tissue-type plasminogen activator--requirement for a co-receptor?
Camani C; Gavin O; Kruithof EK
Thromb Haemost; 2000 Feb; 83(2):290-6. PubMed ID: 10739388
[TBL] [Abstract][Full Text] [Related]
40. Differential endocytosis of tissue plasminogen activator by serpins PAI-1 and PAI-2 on human peripheral blood monocytes.
Lee JA; Croucher DR; Ranson M
Thromb Haemost; 2010 Dec; 104(6):1133-42. PubMed ID: 20838737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
